BRPI0513303A8 - Uso de l-carnitina para o tratamento de doenças cardiovasculares - Google Patents
Uso de l-carnitina para o tratamento de doenças cardiovascularesInfo
- Publication number
- BRPI0513303A8 BRPI0513303A8 BRPI0513303A BRPI0513303A BRPI0513303A8 BR PI0513303 A8 BRPI0513303 A8 BR PI0513303A8 BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A8 BRPI0513303 A8 BR PI0513303A8
- Authority
- BR
- Brazil
- Prior art keywords
- carnitine
- infarction
- treatment
- grams
- days
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE L-CARNITINA PARA O TRATAMENTO DE DOENÇAS CARDIOVASCULARES. A presente invenção refere-se ao uso de L-carnitina, ou um de seus sais farmaceuticamente aceitáveis, é descrito em combinação com glicose para a preparação de um medicamento útil para diminuir o número de mortes causadas por infarto do miocárdio agudo, para reduzir o número de dias gasto por pacientes de infarto em cuidados intensivos em hospital, e para reduzir o número de episódios de insuficiência cardíaca pós-infarto, em que a L-carnitina é administrada intravenosamente dentro apenas de algumas horas do início de sintomas de infarto do miocárdio agudo em uma dose inicial de 9 gramas ao dia em combinação com 1000 a 1500 mL de uma solução de glicose a 5% durante 5 dias, após o que o tratamento com L-carnitina é continuado em uma dose de 4 gramas ao dia administrados oralmente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000346A ITRM20040346A1 (it) | 2004-07-13 | 2004-07-13 | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| PCT/EP2005/006657 WO2006005415A2 (en) | 2004-07-13 | 2005-06-21 | Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0513303A BRPI0513303A (pt) | 2008-05-06 |
| BRPI0513303A8 true BRPI0513303A8 (pt) | 2017-12-26 |
Family
ID=34971575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513303A BRPI0513303A8 (pt) | 2004-07-13 | 2005-06-21 | Uso de l-carnitina para o tratamento de doenças cardiovasculares |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7879908B2 (pt) |
| EP (1) | EP1773314B1 (pt) |
| JP (1) | JP5230195B2 (pt) |
| KR (1) | KR101296479B1 (pt) |
| CN (2) | CN101087602B (pt) |
| AT (1) | ATE542529T1 (pt) |
| AU (1) | AU2005262050B2 (pt) |
| BR (1) | BRPI0513303A8 (pt) |
| CA (1) | CA2569888C (pt) |
| CY (1) | CY1112686T1 (pt) |
| DK (1) | DK1773314T3 (pt) |
| ES (1) | ES2380913T3 (pt) |
| HK (2) | HK1113542A1 (pt) |
| HR (1) | HRP20120178T1 (pt) |
| IT (1) | ITRM20040346A1 (pt) |
| ME (1) | ME01345B (pt) |
| MX (1) | MXPA06014665A (pt) |
| PL (1) | PL1773314T3 (pt) |
| PT (1) | PT1773314E (pt) |
| RS (1) | RS52253B (pt) |
| SI (1) | SI1773314T1 (pt) |
| WO (1) | WO2006005415A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| JPS6415220A (en) | 1987-07-06 | 1989-01-19 | Mitsubishi Electric Corp | Tension control device for utilizing maximum torque and maximum electric current of winding motor |
| JPH06102624B2 (ja) * | 1990-08-10 | 1994-12-14 | アース製薬株式会社 | 非心臓由来の不整脈防止薬 |
| IT1261695B (it) * | 1993-06-02 | 1996-05-29 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono. |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| CA2352485A1 (en) * | 1998-11-26 | 2000-06-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
| HUP0203441A3 (en) * | 1999-10-11 | 2004-01-28 | Sigma Tau Ind Farmaceuti | Use of l-carnitine and its alkanoyl derivatives as osmotic agents and solutions for medical use |
| CA2480557C (en) * | 2002-04-01 | 2013-02-19 | Gary David Lopaschuk | Cycloalkylcarboxyl derivatives that stimulate glucose utilization and methods of use |
| ITRM20030178A1 (it) * | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
-
2004
- 2004-07-13 IT IT000346A patent/ITRM20040346A1/it unknown
-
2005
- 2005-06-21 DK DK05755616.9T patent/DK1773314T3/da active
- 2005-06-21 AT AT05755616T patent/ATE542529T1/de active
- 2005-06-21 JP JP2007520688A patent/JP5230195B2/ja not_active Expired - Fee Related
- 2005-06-21 BR BRPI0513303A patent/BRPI0513303A8/pt not_active Application Discontinuation
- 2005-06-21 CA CA2569888A patent/CA2569888C/en active Active
- 2005-06-21 PT PT05755616T patent/PT1773314E/pt unknown
- 2005-06-21 KR KR1020077000711A patent/KR101296479B1/ko active IP Right Grant
- 2005-06-21 CN CN2005800234751A patent/CN101087602B/zh not_active Expired - Fee Related
- 2005-06-21 MX MXPA06014665A patent/MXPA06014665A/es not_active Application Discontinuation
- 2005-06-21 EP EP05755616A patent/EP1773314B1/en active Active
- 2005-06-21 ES ES05755616T patent/ES2380913T3/es active Active
- 2005-06-21 ME MEP-2012-32A patent/ME01345B/me unknown
- 2005-06-21 WO PCT/EP2005/006657 patent/WO2006005415A2/en active Application Filing
- 2005-06-21 SI SI200531481T patent/SI1773314T1/sl unknown
- 2005-06-21 AU AU2005262050A patent/AU2005262050B2/en not_active Ceased
- 2005-06-21 RS RS20120095A patent/RS52253B/en unknown
- 2005-06-21 CN CN201110226409.1A patent/CN102349923B/zh not_active Expired - Fee Related
- 2005-06-21 PL PL05755616T patent/PL1773314T3/pl unknown
- 2005-06-21 US US11/629,202 patent/US7879908B2/en active Active
-
2008
- 2008-03-13 HK HK08102916.9A patent/HK1113542A1/xx not_active IP Right Cessation
-
2010
- 2010-12-20 US US12/972,617 patent/US8394854B2/en active Active
-
2012
- 2012-02-22 HR HRP20120178TT patent/HRP20120178T1/hr unknown
- 2012-04-05 CY CY20121100341T patent/CY1112686T1/el unknown
- 2012-07-10 HK HK12106717.5A patent/HK1166003A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaspan et al. | Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function | |
| FI3628319T3 (fi) | Hepaattisen enkefalopatian hoito rifaksimiinilla | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| PL404315A1 (pl) | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku | |
| AR036312A1 (es) | Composicion farmaceutica | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| BRPI0513303A8 (pt) | Uso de l-carnitina para o tratamento de doenças cardiovasculares | |
| PT1408977E (pt) | Terapia de combinacao para o tratamento de falha cardiaca | |
| MXPA05007612A (es) | Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. | |
| JP4381685B2 (ja) | ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用 | |
| Martorell-Calatayud et al. | Multiple painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea | |
| JP2006045200A (ja) | 間質性膀胱炎の治療薬 | |
| ROY et al. | Milestones In Diabetes Research | |
| McDaniel | Antidepressant activity of linezolid | |
| Ayache et al. | Methylphenidate in a patient with depression and respiratory insufficiency | |
| Prabhu et al. | Digital gangrene due to dopamine infusion-a case report | |
| Shankar et al. | Hyperglycemia induced hemichoreoathetosis, an uncommon presenting symptom of diabetes mellitus | |
| JP2022546134A (ja) | 自閉症スペクトル障害の治療における使用のためのバフィデムスタット | |
| JP2008517872A5 (pt) | ||
| Okonta | Pharmacodynamic drug interaction study: effect of sertraline on the hypoglucemic action of glibenclamide in rats | |
| Placebo-Controlled | Original Research Efficacy and Safety of Adjunctive Armodafinil | |
| Michel et al. | 778 EVALUATION OF FESOTERODINE EFFICACY OVER 24 HOURS FOLLOWING ONCE-DAILY DOSING IN SUBJECTS WITH OVERACTIVE BLADDER | |
| UA70535A (en) | Method for preventing paroxysms of atrial fibrillamethod for preventing paroxysms of atrial fibrillation in ischemic disease of heart in elderly tion in ischemic disease of heart in elderly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ALFASIGMA S.P.A. (IT) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |